Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

专利摘要:
The present invention relates to novel peptides capable of modulating the activity of calcium channels in cardiac cells. More specifically, the present invention provides a method of contacting a cardiac lianodine receptor (RyR2) with an amount of dihydropyridine receptor (DHPR) polypeptide sufficient to modulate the activity of RyR2, and measuring the activity of the calcium channel. It provides a method of regulating the activity of the heart calcium channel comprising a. The methods of the present invention are useful in a series of disorders and disorders associated with cardiac dysfunction, particularly diseases and disorders including reduced cardiac output and / or abnormal excitatory-constriction binding, calcium overload, or calcium outflow in cardiac cells.
公开号:KR20040002970A
申请号:KR10-2003-7014989
申请日:2002-05-17
公开日:2004-01-07
发明作者:덜헌티안젤라페이；캐사로토마르코지오바니
申请人:디 오스트레일리언 내셔널 유니버시티；
IPC主号:

专利说明:

METHOD OF MODULATING THE ACTIVITY OF CALCIUM CHANNELS IN CARDIAC CELLS AND REAGENTS THEREFOR}
[2] Detailed bibliographic information of the documents mentioned herein is included at the end of this specification. References to prior art listed herein, including one or more prior art documents, are not believed to admit or imply that the prior art is general knowledge in Australia or forms part of general knowledge in Australia.
[3] Excit-constriction coupling, which associates electrical excitation with mechanical activity, is important for the function of transverse muscles such as heart and skeletal muscle. The major components of the excitatory-constriction bonds are the dihydropyridine receptor (DHPR), the voltage-dependent Ca ²⁺ channel of the transverse tubule (TT), and the near vesicles (SR), which open to release calcium from the endoplasmic reticulum (SR) into the cytoplasm. Ca ²⁺ release channel or lianodine receptor (RyR) on the membrane.
[4] Cardiac cells and skeletal muscle cells have different isotypes of both RyRs and DHPRs. In particular, RyR1 and DHPR-isotype 3 dominate in skeletal muscle, and RyR2 and DHPR-isotype 1 dominate in cardiac cells. The homology between RyR1 and RyR2 amino acid sequences is only about 70%.
[5] In skeletal muscle, the ryanodine receptor (RyR1) is activated by protein-protein interactions with 138 amino acid cytoplasmic loops between repeats II and III of the DHPR α-1 subunit (Tanabe et al., 1990, Nature 346: 567). -568). It was determined whether the skeletal DKPR cytoplasmic loop region sufficient to activate skeletal muscle RyR1-mediated calcium release is within the 20 amino acids of Thr ⁶⁷¹ to Leu ⁶⁹⁰ (El Hayek et al., 1995, J. Biol. Chem. 270: 22116-22118 Dulhunty et al., 1999, Biophys. J. 77: 189-203; and Gurrola et al., 1999, J. Biol. Chem. 274: 7879-7886). Four strict DHPR molecules in skeletal muscle are located in the tetrad structure of DHPR at two RyR1 polypeptide intervals in a strict geometry that is considered important for normal excitatory-constriction binding. During the excitatory phase of DHPR, such as by electrical stimulation, protein-protein interactions lead to calcium outflow from SR, possibly leading to structural conversion of the RyR1 polypeptide, which leads to channel opening. Thus, excitatory-contraction binding in skeletal muscle is essentially a calcium-independent process.
[6] In contrast, excitatory-contraction coupling in cardiac muscle involves a calcium release (CICR) mechanism (Niggli, 1999, Ann Rep Physio 1 61: 311-335). Their excitation following the opening of the cardiac DHPR calcium channel results in a small amount of extracellular calcium influx into the cardiomyocytes by voltage-dependent L-type calcium channels (ie cardiac DHPR) that are activated during each action potential. The first signal that acts as an attractant for other CICRs from intracellular calcium is retained in the SR. Secondary calcium release from SR is caused by cardiac RyR2 calcium release channels. In most mammals, CICR magnifies the original signal attractant several times, keeping the stoichiometry of cardiac RyR2 molecules versus cardiac DHPR constant at about 16: 1.
[7] Although cardiac CICR requires an initial increase in cytoplasmic Ca ²⁺ to attract calcium release from SR, it does not appear to be self-sustaining. This is because CICR is generally localized to each cell, but is probably only propagated between cardiomyocytes overloaded with calcium. Furthermore, the heart muscle contractile force is from about ^{3 × 10 -7 M [Ca 2+} ] i to about 10 ^-6 M [Ca ^2+] i in the [Ca ^2+] i increases proportionally, CICR all reaction or It suggests that it does not react at all.
[8] In contrast to excitatory-constriction binding in skeletal muscle cells, it is not known whether there is any direct protein-protein interaction between cardiac DHPR and cardiac RyR2 in vivo. However, the cytoplasmic loops of the skeletal DHPR α-1 subunit did not bind to cardiac RyR2 in two hybrid assays (Osterland et al., 1999, Biophys. J. 76: A467 (green)), and the skeletal DHPR α-1 subunits. The 20-mer peptides of the unit cytoplasmic loops (ie Thr ⁶⁷¹ to Leu ⁶⁹⁰ ) did not bind RyR2 in surface plasmon resonance studies (O'Reilly and Ronjat, 1999, Biophys. J: 76: A466- (green)) .
[9] Potential data indicate that the relationship between skeletal and cardiac DHPR and RyRs channels is different. For example, cardiac RyR2 expressed in myocytes lacking skeletal RyR1 but containing skeletal DHPR α-1 subunit could not support the skeletal form of excitatory-constriction binding. Moreover, isolated RyR2 channels are not activated by the former 138-amino acid cytoplasmic loop between repeat units II and III of the cardiac or skeletal DHPR α-1 subunit (Lu et al., 1994, J. Biol. Chem. 269: 6511). -6516). Furthermore, despite the fact that the 20-mer peptides of the skeletal DHPRα-1 subunit cytoplasmic loops (ie, Thr ⁶⁷¹ to Leu ⁶⁹⁰ ) are high affinity activators of skeletal muscle RyR1 channels, they do not induce Ca ²⁺ release from cardiac SR Or, it does not enhance the binding of the RyR2 channel with [ ³ H] lianodine (El Hayke et al., 1995, homology). Moreover, the 20-mer peptides (ie Thr671 to Leu690) of the skeletal DHPRα-1 subunit cytoplasmic loops were unable to activate cardiac RyR2 channels, for example by prolonging their open time or by opening frequency.
[10] Stern (1992, FASEB J. 6: 3092-3100) found that Ca ²⁺ synapses (ie very high Ca ²⁺ localization domains near the Ca ²⁺ inlet and release sites) were associated with the activity of DHPR and RyRs in cardiac tissue. Functionally related. Each Ca ²⁺ synapse allows for local regulation of RyR2 by high local Ca ²⁺ concentrations, resulting in the high signal amplification observed without spreading Ca ²⁺ release signals throughout the whole cell or between cells. Thus, the number of release units was replenished while each signal proceeded quantitatively, attracting calcium release. This suggestion is consistent with the observation of calcium sparks of short duration (about 50 ms) and limited spatial expansion (about 1.5 μm) during stimulation of cardiac myocytes.
[11] Myocardial contractile insufficiency is a common cause of morbidity and mortality in patients with systemic inflammatory conditions such as ischemic heart disease, congestive heart failure, and sepsis. Accumulated evidence indicates that systolic dysfunction is associated with dysregulation of myocardial calcium flow. Reduced Ca ²⁺ sensitivity of muscle filaments, or degeneration of calcium signaling such as, for example, degeneration or rupture of calcium synapses, degeneration of RyR2, or degeneration of DHPR, can lead to a decrease in cardiac contractility. Some Ca ²⁺ signaling pathways are adversely affected during heart failure or cardiac hypertrophy (calcium overload at the end of heart failure). Increased resting Ca ²⁺ concentrations, decreased Ca ²⁺ transients, slowed down relaxation, and modified Ca ²⁺ pumps in SR were observed in heart failure tissues or cardiac hypertrophy tissues.
[12] More specifically, cardiac hypertrophy as well as heart failure show reduced excitatory-contraction binding efficacy compared to normal heart (Gomez et al., 1997, Science 276: 755-756). However, in heart failure or cardiac hypertrophy, each DHPR and RyRs appear normal, suggesting that there may be an impairment in the binding between these two calcium signal proteins. This view is supported by the recovery of normal excitatory-constriction binding by the use of β-adrenergic agonists to prolong the open time of cardiac DHPR in cardiac hypertrophy cells or following congestive heart failure.
[13] Moreover, hyperphosphorylation of RyR2 in human heart failure results in impaired channel function.
[14] Moreover, cardiac output can be increased by "promoters" that promote excitatory-contraction coupling in acute situations such as heart attacks. Distinct regions of the myocardium are refined during ischemic episodes resulting in reduced cardiac output. Blood supply to essential organs such as the brain can be maintained by more strongly constricting the remaining healthy myocardium. This is usually done by drugs that increase cAMP by mimicking β-adrenergic stimulation to stimulate DHPR activity and excitatory-constriction binding. Long term increased cAMP levels can be toxic and cause calcium overload.
[15] (Summary of invention)
[16] This specification includes nucleotide and amino acid sequence information prepared using the Program Patent Version 3.1 (PatentLin Version 3.1), provided after the bibliographic information at the end of the present application. Each nucleotide or amino acid sequence is identified by the sequence shown by the numeral designation <210> followed by the sequence designation (eg, <210> 1, <210> 2, etc.). The length, type (DNA, protein (PRT), etc.) of the sequence and feed organisms for each nucleotide or amino acid sequence are provided in the numeral fields <211>, <212>, and <213>, respectively. Nucleotide and amino acid sequences referred to herein are defined by the numeral “SEQ ID NO:” followed by a numerical designation. For example, SEQ ID NO: 1 refers to information provided in the designated numerical display column &lt; 400 &gt;
[17] The list of consensus sequences provided as SEQ ID NO: 1 includes a list of one or more amino acid sequences set forth in SEQ ID NO: 2-7 used to collect the consensus sequences.
[18] The amino acids at positions 6 and 8 of SEQ ID NO: 1 may be any amino acid, preferably Ala or Glu; The amino acid at position 7 may be any amino acid, preferably Glu or Lys; Xaa at positions 11, 14, and 18 is Arg or Lys; Xaa at position 12 can be any amino acid, preferably Arg or Glu, and Xaa at position 18 can be any amino acid, preferably Gly, Thr, Ala; Xaa at position 19 may be any amino acid, preferably Leu, Ala or Asn.
[19] In this specification, the term “comprises” or “comprising”, “comprising”, unless otherwise defined in the context, means including a specified step or element or whole or a group of steps or elements or whole, but some other It is not intended to exclude steps or elements or whole or a group of elements or wholes.
[20] As used herein, the term “derived from” does not necessarily need to be obtained directly from a source, but may be used to indicate a specific integral that can be obtained from a particular source.
[21] In the study leading to the present invention, the inventors sought to identify new methods of modulating CICR in cardiac tissue to provide an improved therapeutic regimen for heart failure and / or cardiac hypertrophy. Surprisingly, although no physical association has been established between cardiac DHPR and cardiac RyRs, the present invention provides small fragments of a backbone or cardiac DHPR polypeptide capable of activating cardiac RyR2 channels, such as, for example, small basic charged peptides. .
[22] More specifically, we found that the 20-mer peptides of the backbone DHPR α-1 subunits (ie, Thr ⁶⁷¹ to Leu ⁶⁹⁰ ) show significant activity of the RyR2 channel at −40 mV and strong inhibition at +40 mV. Revealed. Cardiac RyR2 activity was observed at low concentrations, such as 1 mM peptide, significantly lower than the peptide concentration required to activate skeletal muscle RyR1. Moreover, cardiac RyR2 channels were significantly more inhibited than those observed for skeletal RyR1 channels with 3 × 10 ⁻⁷ M cytoplasmic Ca ²⁺ .
[23] Thus, a cardiac ryanodine receptor (RyR2) calcium channel comprising contacting a cardiac RyR2 with an amount of dihydropyridine receptor (DHPR) polypeptide fragment, eg, a basic charged fragment, sufficient to modulate the activity of RyR2. It provides a method of regulating the activity of.
[24] More specifically, the invention relates to contacting a cardiac RyR2 with a fragment of a dihydropyridine receptor (DHPR) polypeptide sufficient to modulate the activity of RyR2, eg, a basic charged fragment, and the cardiac RyR2 calcium Provided is a method of modulating the activity of a cardiac linodine receptor (RyR2) comprising measuring the activity of a channel.
[25] Embodiments of the present invention from the foregoing discussion include contacting cardiac RyR2 with a fragment of dihydropyridine receptor (DHPR) polypeptide sufficient to enhance the activity of RyR2, and measuring the activity of the cardiac RyR2 calcium channel. It will be evident that the present invention relates to a method for enhancing the activity of a cardiac lianodine receptor (RyR2). In accordance with the specific examples herein, and without limiting the invention to any theory or mode of action or effective peptide concentration, we found that in the case of cardiac RyR2 isolated from a lipid bilayer, both the channel opening frequency and the duration of each channel opening It was found to be enhanced by the addition of about 1 nM peptide to about 10 μM peptide. At high peptide concentrations, the activity of open channels initially decreases slightly, but the activity of other channels becomes more pronounced to reflect microheterogeneity in RyR2 channel sensitivity to peptides.
[26] Another embodiment of the invention comprises contacting cardiac RyR2 with an amount of dihydropyridine receptor (DHPR) polypeptide fragment sufficient to inhibit the activity of RyR2, and determining whether the cardiac RyR2 calcium channel is deficient in activity. It relates to a method for inhibiting cardiac RyR2 calcium activity comprising. Without limiting the invention to any theory or mode of action or effective peptide concentration, we found that in the case of cardiac RyR2 isolated from the lipid bilayer, the channel open frequency, particularly at +40 mV, is probably distinguished from the site of binding during the channel activator. It is reduced to a concentration of at least about 10 μM peptide as a result of the peptide binding in the pore of the RyR2 channel at the site.
[27] A second aspect of the invention provides a method of identifying peptide modulators of cardiac RyR2 calcium channel, the method
[28] (i) incubating the amount of a dihydropyridine receptor polypeptide or a homologue, analog or derivative thereof that modulates cardiac RyR2 channel activity in the presence of a functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be modulated, Measuring channel activity;
[29] (ii) incubating the candidate peptide in the presence of the functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be regulated by the dihydropyridine receptor polypeptide or homologue, analog or derivative thereof, and inactivating the channel Measuring;
[30] (iii) comparing the activities of (i) and (ii); And
[31] (iv) preferably selecting a peptide having similar or enhanced control of channel activity in (ii) compared to (i).
[32] In an alternative embodiment, aspects of the invention provide a method of identifying a peptide modulator of a cardiac RyR2 calcium channel, the method comprising
[33] (i) incubating the amount of a fragment of the dihydropyridine receptor polypeptide or homolog, analog or derivative thereof that modulates the cardiac RyR2 channel in the presence of a functional cardiac RyR calcium channel under suitable conditions in which calcium channel activity can be modulated, and Measuring the activity of the;
[34] (ii) a candidate peptide that modulates candidate cardiac RyR2 channel activity in the presence of the functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be regulated by the dihydropyridine receptor polypeptide or homolog, analog or derivative thereof, and Incubating the amount of the dihydropyridine receptor polypeptide or homologue, analog or derivative thereof, and measuring the activity of the channel;
[35] (iii) comparing the activity in (i) and (ii); And
[36] (iv) preferably, selecting peptides having similar or enhanced channel activity regulation in (ii) as compared to (i).
[37] A third aspect of the invention provides a method of contacting a cardiac RyR2 channel with an amount of a fragment of a dihydropyridine receptor (DHPR) polypeptide or a homologue, analog or derivative thereof under sufficient time and conditions to bind to the channel, and the peptide and A method of determining whether a cardiac RyR2 channel is open or has a high channel open probability, comprising measuring a channel binding, wherein the binding of the peptide to the channel exhibits a high channel open probability and a nonspecific peptide binding. Denotes a low channel open probability.
[38] A fourth aspect of the invention includes treating the cardiac dysfunction by administering an effective amount of a dihydropyridine receptor (DHPR) polypeptide or homolog, analogue or derivative fragment under a time and condition sufficient for enhanced heart contraction. A method of treating cardiac dysfunction in a human or animal subject is provided.
[39] A fifth aspect of the invention provides a pharmaceutical composition of a dihydropyridine receptor polypeptide fragment comprising at least five amino acid residues of a peptide or homologue, analog or derivative thereof set forth in any one of SEQ ID NOs: 1-10. do.
[40] As used herein, single letter and three letter abbreviations are defined in Table 1.
[41] 1- and 3-letter amino acid abbreviations amino acid 3-letter abbreviation 1 character symbol Alanine Ala A Arginine Arg R Asparagine Asn N Aspartic acid Asp D Cysteine Cys C Glutamine Gln Q Glutamic acid Glu E Glycine Gly G Histidine His H Isoleucine Ile I Leucine Leu L Lee Sin Lys K Methionine Met M Phenylalanine Phe F Proline Pro P Serine Ser S Threonine Thr T Tryptophan Trp W Tyrosine Tyr Y Valine Val V Any residue or as not otherwise defined Xaa X
[1] The present invention generally relates to novel peptides capable of modulating the activity of calcium channels in cardiac cells. More specifically, the present invention relates to a method of contacting a cardiac lyanodine receptor (RyR2) with an amount of dihydropyridine receptor (DHPR) fragment sufficient to modulate the activity of RyR2, and measuring the activity of the calcium channel. It provides a method of regulating the activity of the heart calcium channel comprising a. The methods of the present invention are directed to the treatment of a series of disorders and disorders associated with diseases and disorders, including cardiac dysfunction, in particular reduced cardiac output and / or non-ideal excitatory-contraction coupling, calcium overload, or calcium efflux in cardiac cells. useful.
[42] 1 is a schematic showing the sequenced amino acid sequence of several cardiac and skeletal DHPR polypeptide cytoplasmic loops as follows: human skeletal muscle DHPR-3 (SEQ ID NO: 2; Drouet et al., 1993); Murine skeletal muscle DHPR-3 (SEQ ID NO: 3; Chaudhari, 1992); Rabbit skeletal muscle DHPR-3 (SEQ ID NO: 4; Tanabe et al., 1987); Rabbit heart DHPR-1 (SEQ ID NO: 5); Rabbit heart DHPR-1 (SEQ ID NO: 6); And Edible Frog Skeletal Muscle DHPR-3 (SEQ ID NO: 7; Zhou et al., 1998). Consensus sequences (SEQ ID NO: 1) are shown in bold, based on comparisons with available sequences. The amino acid sequences of the nonspecific peptides NB (SEQ ID NO: 8) and A1S (SEQ ID NO: 9) are also shown.
[43] FIG. 2 shows 20- of the skeletal DHPR cytoplasmic loop (SEQ ID NO: 2) added to the cytoplasmic (cis) plane of cardiac RyR2 isolated from the lipid bilayer in the presence of cis 10 ^-7 M Ca ²⁺ when measured at -40 mV. It is a graph showing that mer peptides increase the activity of cardiac RyR2. Signal channel activity was measured at −40 mV in the absence of added peptides (Panel A), or in the presence of 65 nM peptides (PANEL B), or 6.5 μM peptides (PANEL C).
[44] On the left side of each panel, the downward channel opening is indicated at -40 mV, where the zero potential (close) level is indicated by dashed line "C" and the maximum single conductance is indicated by solid line "O". After addition of the peptide, two channels are activated in the bilayer of -40 mV.
[45] The right side of each panel is a graph showing all points during the 30s recording period. The numbers on the x-axis represent the amplitude of the channel openings, and the abscissa represent the percentage of total openings at each amplitude. Negative numbers represent negative (internal) channels at -40 mV.
[46] Figure 3 shows that 20-mer peptide (SEQ ID NO: 2) of the skeletal DHPR cytoplasmic loop added to cytosolic (cis) solution in the presence of cis 10 ^-7 M Ca ²⁺ at +40 mV increased cardiac RyR2 activity. It is a graph showing decreasing. Single channel activity was measured at +40 mV in the absence of added peptide (Panel A) or in the presence of 65 nM peptide (Panel B) or 32.5 μM peptide (Panel C).
[47] On the right side of each panel, the upward channel opening is indicated at +40 mV, where the zero current (close) level is indicated by dashed line “C” and the maximum single channel conductance is indicated by solid line “O”. The channels are mostly open at 65 nM concentration. In contrast, the channel is absent of peptide but is mostly closed in 32.5 μM peptide.
[48] The right side of each panel is a graph showing all points during the 30 second recording period. The number on the x-axis represents the amplitude of the channel opening, and the abscissa represents the percentage of total opening at each amplitude. The number represents the channel opening at +40 mV.
[49] 4 shows the average normalized mean current (coordinate) as a function of peptide concentration (ie, log ₁₀ [eptide (nM))) of cytoplasmic solution (x-axis) at −40 mV (panel A) and +40 mV (panel B). It is a graph. Normalized mean current (I'p / I'c) is the ratio of mean current in the presence of peptide (ie, I'p) to mean current in the absence of peptide (ie, I'c) under control conditions. Data represent mean mean current ± SEM. Samples were 20-mer peptides of the backbone DHPR cytoplasmic loop represented by SEQ ID NO: 2 (n = 8, ●), non-specific peptide NB represented by SEQ ID NO: 8 (n = 2, ▲), or SEQ ID It contained the non-specific peptide A1S (n = 3, ■) represented by NO: 9. Normalized average current of 1.0 or greater indicates activation of cardiac RyR2 channels by peptides. Thus, the data show significant activation of cardiac RyR2 channels by peptides (SEQ ID NO: 2) up to 10 μM at +40 mV or higher concentrations at −40 mV.
[50] 5 is a graph showing that peptides increase Ca ²⁺ − and caffeine-activated Ca ²⁺ release from cardiac SR vesicles. The extrafoveal solution at the concentration shown on the abscissa under control conditions or after addition of 20 μM Ca ²⁺ or 2 mM caffeine (at peptide concentration 0) and after addition of peptide only (small symbol), or 20 μM Ca ²⁺ or 2 mM caffeine And the initial rate of Ca ²⁺ release after addition of the peptide (large symbol). The Ca ²⁺ release rate is given as μmol of Ca ²⁺ per minute, per mg of protein in SR vesicles. Data is shown as SEQ ID NO: 2 (black circles), SEQ ID NO: 8 (black squares), SEQ ID NO: 9 (white circles) and SEQ ID NO: 10 (white squares). Results are presented as mean ± sem of at least 5 observations for each concentration.
[51] FIG. 6 is a graph showing the effect of SEQ ID NO: 9 on mean current flow through RyR channels bound to lipid bilayers at cis (cytoplasmic) Ca ²⁺ concentration of 100 μM. Data were obtained by recording for 60 seconds at a bilayer potential of -40 mV (top graph) and +40 mV (bottom graph). The data points represent the average relative average currents from 6 experiments (average currents using peptide divided by the average currents under control standard conditions) and vertical bars represent ± 1 sem. Channel activity is clearly lowered in a concentration-dependent manner by the peptide and has the maximum effect on 100 nM peptides. The degradation in the 100 nM peptide was significantly greater at +40 mV (asterisk) than at -40 mV.
[52] FIG. 7 is a graph showing the effect of SEQ ID NO: 9 on mean current flow through the RyR channel bound to the lipid bilayer at a cis (cytoplasmic) Ca ²⁺ concentration of 100 nM. Data were obtained by recording for 60 seconds at a bilayer potential of -40 mV (top graph) and +40 mV (bottom graph). The data points represent the average relative average currents from 7 experiments (average currents using peptide divided by the average currents under control standard conditions) and vertical bars represent ± 1 sem. Channel activity is clearly enhanced by the peptides in a concentration-dependent manner and has maximum effect on 100 nM peptides. The degradation in> 100 nM peptides was seen at +40 mV, which is a sign of some pore block.
[53] 8 is a graph showing SEQ ID NO: 9 efficacy for single channel parameters as a function of peptide concentration. Data is shown at -40mV (left panel) and + 40mV (right panel). The top graph shows the open probability of the channel, the second graph shows the average open probability, then the average close time, and the last shows the frequency of the channel opening. Data points represent mean parameter values from seven experiments and vertical bars represent ± 1 sem. The decrease in the closing time of the channel and the continuous increase in the frequency contribute most strongly to the increase in the open probability.
[54] One aspect of the invention provides for the activity of a cardiac ryanodine receptor (RyR2) calcium channel comprising contacting a cardiac RyR2 channel with an amount of dihydropyridine receptor (DHPR) polypeptide fragment sufficient to modulate the activity of the RyR2. It provides a way to adjust.
[55] More specifically, the present invention provides a method of contacting a cardiac RyR2 channel with an amount of dihydropyridine receptor (DHPR) polypeptide fragment sufficient to modulate the activity of the RyR2, and measuring the activity of the cardiac RyR2 calcium channel. It provides a, including a method of regulating the activity of the cardiac lyanodine receptor (RyR2) calcium channel.
[56] As used herein, the term "rianodine receptor-2 channel" or "RyR2 channel" or "heart RyR channel" will be used to refer to a calcium channel comprising a RyR2 polypeptide subunit. Those skilled in the art are aware of the physical structure of the "RyR2 channel" or "heart RyR channel" as used herein.
[57] As used herein, the term “modulating” will be used to mean enhancing or inhibiting the activity of the RyR2 channel. Thus, "modifying the activity of the RyR2 calcium channel" or similar terms generally refer to, for example, calcium sensitivity of calcium synapses or cardiac RyR2, during each action potential, or opening frequency of each cardiac RyRs, or each By CICR, such as modifying the open period of cardiac RyRs, it is meant to be modified (ie, enhanced or reduced).
[58] As mentioned above, the present invention clearly includes both methods of enhancing the activity of RyR2 calcium channels and methods of inhibiting the activity of cardiac RyR2 calcium channels.
[59] Cardiac RyR2 channels may be present in cardiac cells in situ or in the myocardium in vivo. However, it may also be a separate RyR2 channel, such as for example inserted into a lipid bilayer, or alternatively, for example, recombinant such as expressed on the membrane of transfected cells (eg CHO cells or myocytes). Or a reconfigured RyR2 channel. For example, standard procedures as described by Bhat et al. (1997, Biophys. J. 73: 1329-1336), incorporated herein by reference, can be used to express RyR2 channels in transfected cells. Preferably, the cardiac RyR2 channel is in situ in cardiac cells or is in vivo in cardiac tissue.
[60] As used herein, the term “fragment” refers to a positive charge overall at physiological pH values by, for example, the presence of relatively high proportions of basic amino acid residues such as arginine or lysine, or semi-basic amino acid residues such as histidine. Branch refers to a peptide. Preferably, the fragment will contain at least about 25% basic amino acid residues, and more preferably at least about 50% basic amino acid residues.
[61] Peptides useful for carrying out the invention are, in terms of length, the amino acid sequence TSAQKXXSEE (R / K) XR (R / K) K (M / L) (A / S) (R / K) XX (SEQ ID NO: 1 At least about 5 amino acids from a cardiac or backbone dihydropyridine receptor (DHPR) polypeptide fragment, wherein X is any amino acid residue. The present invention extends to the use of peptides having sequences similar to SEQ ID NO: 1 from any source, such as, for example, synthetic or naturally-occurring peptides or peptides derived from any DHPR sequence.
[62] For the purpose of further describing the invention, the amino acid sequence set forth in SEQ ID NO: 1 corresponds to the 20-mer peptide consensus sequence for the cytoplasmic II-III loop of DHPR of skeletal muscle and myocardium of several animal species, as indicated in FIG. 1. do. As embodied herein, the inventors have discovered that a portion of the cytoplasmic II-III loop of human skeletal muscle DHPR-3 regulates both RyR2 channel activity. Close sequence correlations between the various DHPRs listed in FIG. 1 indicate that any peptide having a sequence of SEQ ID NO: 1 or a sequence substantially identical to SEQ ID NO: 1 will modulate RyR2 channel activity.
[63] Thus, the present invention extends to the use of any and all homologues, analogs and derivatives of the amino acid sequence set forth in SEQ ID NO: 1. Preferably, such homologues, analogs, or derivatives will carry a basic charged peptide, more preferably a preserved basic residue of SEQ ID NO: 1.
[64] More preferably, the subject sequence comprises the motif RKRRK at amino acid positions 11-15 of SEQ ID NO: 1.
[65] As used herein, the “homolog” of SEQ ID NO: 1-7 is derived from a natural or synthetic basic charged peptide derived directly from a backbone or cardiac DHPR amino acid sequence, or from another particular source, or alternatively, a RyR2 channel regulatory activity. Refers to a similar sequence by screening a peptide that mimics and comprises any of the sequences corresponding substantially to SEQ ID NO: 1 or the specific amino acid sequence listed included in SEQ ID NO: 2-7.
[66] For example, the amino acid of any one of SEQ ID NOs: 1-7 is for example hydrophobic, hydrophilic, hydrophobic, antigenic, provided that the overall characteristics of the peptide (eg, basic charge or structure) are maintained. It may be substituted by other amino acids having similar properties, such as the tendency to form a charge or α-herlix structure.
[67] Substitutions include amino acid alterations in which amino acids are substituted with different naturally-occurring or non-normal amino acid residues. Such substitutions may be made when the amino acid residues are substituted with different amino acid residues of similar properties such as, for example, Gly ↔ Ala, Val ↔ Ile ↔ Leu ↔ Met, Asp ↔ Glu, Lys ↔ Arg, or Asn ↔ Gln. Can be classified as " Amino acid substitutions are representative of a single residue, but can be multiple residues, dense or dispersed.
[68] In particular, homologs which are synthetic peptides prepared by any method known to those skilled in the art, such as solid phase methods using Fmoc amino acids in automated peptide synthesizers, are in particular contemplated herein. Such peptides can be cyclized by conventional procedures and / or can be partially purified to be free of substantially nonspecific peptides.
[69] The “analog” of any one of SEQ ID NOs: 1-7 includes an amino acid sequence that is substantially identical to the sequence or analog thereof, despite the occurrence of one or more non-naturally occurring amino acid analogs therein. Particularly preferred analogs include any peptide or non-peptide mimetic of any one of SEQ ID NOs: 1-7 that retains the characteristics of the sequence, such as, for example, charge distribution or conformation or other structural features. Imperatoxin peptides disclosed by Gurrola et al. (1999, J. Biol. Chem. 274: 7879-7886), and certain synthetic nonpeptide mimetics, are particularly contemplated by the present invention.
[70] The term "derivative" related to any one of SEQ ID NOs: 1-7 will be used to refer to any part, fragment or polypeptide fusion of the sequence or homologue or analog thereof. Derivatives may include ligands such as lipids, liposaccharides, lipopolysaccharides (LPS), carbohydrates, enzymes, peptides, radionuclides, fluorescent compounds, photoactivable residues (e.g., p-benzoyl-phenylalanine), Or a modified amino acid sequence or peptide attached to one or more amino acid residues contained therein, such as a glucosyl moiety. Processes for derivatizing peptides are well known in the art.
[71] For example, preferred derivatives may comprise fragments of any one of SEQ ID NOs: 1-7 or fragments of homologues or analogs of any one of SEQ ID NOs: 1-7. Amino acid deletions will generally be about 1-15 amino acid residues in length. The deletion is preferably made at the N-terminus or C-terminus of SEQ ID NO: 1.
[72] Alternatively, the derivative of any one of SEQ ID NOs: 1-7 may be an additional amino acid residue added at the N-terminus or C-terminus of the peptide or homologue or analog thereof. Insertion will generally be small enough to not interfere with access to the RyR2 channel, such as, for example, insertion of about 1-4 amino acid residues.
[73] Preferred homologs, analogs and derivatives of any one of SEQ ID NOs: 1-7 include at least about 5 consecutive amino acids, more preferably at least about 10 consecutive amino acid residues or more of any one of SEQ ID Nos: 1-7. It will preferably comprise at least about 15-20 consecutive amino acid residues. Thus, such homologues, analogs and derivatives may be full length or smaller than the full length sequence, as compared to SEQ ID NO: 2-7.
[74] As far as RyR2 channel regulatory activity is concerned, in addition to being processed into a functional equivalent to SEQ ID NO: 1, preferred homologs, analogs or derivatives comprise amino acid sequences having at least about 70% homology with SEQ ID NO: 1. Will include. Preferably, the rate homology with SEQ ID NO: 1 will be at least about 80%, more preferably at least about 90% and even more preferably at least about 95% or at least about 98 or 99%. In determining whether two amino acid sequences fall within a defined ratio homology or similarity range, one of ordinary skill in the art will recognize that it is necessary to perform side-by-side comparisons of amino acid sequences. In this comparison or arrangement, the difference will be to locate nonhomologous amino acid residues based on the algorithm used to perform the arrangement. In the present specification, the rate homology and similarity between two or more amino acid sequences will be used to refer to the number of each homologous residue and similar residue between the sequences as measured using any standard algorithm known to those skilled in the art. In particular, amino acid homology and similarity are found in Neeledman and Wunsch (1970, J. Mol Biol. 48: 443) in order to maximize the number of homology / similar amino acids and to minimize the number and / or length of sequence gaps in the array. Or use the GAP program of the United States, Madison, University Research Park, Computer Genetics Inc. (Devereaux et al, 1984, Nucl. Acids Res. 12: 387-395), or alternatively, The array is calculated using the CLUSTAL W algorithm (1994, Nucl. Acids Res. 22: 4673-4680).
[75] In the regulation of cardiac RyR2 channel activity, particularly preferred homologs, analogs, or derivatives of SEQ ID NO: 1 will successfully compete with any of SEQ ID NOs: 2-7. In standard competition studies, RyR2 channel regulatory activity was assayed at different concentrations of peptides tested, such as in the presence of SEQ ID NO: 2 concentrations, for example to enhance or inhibit cardiac RyR2 channel activity. The high affinity activator of the cardiac RyR2 channel successfully enhances channel activity in the lipid bilayer at a cytosolic calcium concentration of about 10 ⁻⁷ M to about 10 ⁻⁵ M, and known activator peptides (eg, about 1 nM SEQ ID NO: 2 to about 100 nM SEQ ID NO: 2) to determine its activity competing with the enhancement of channel activity induced. Similarly, high affinity inhibitors of cardiac RyR2 channels successfully inhibit channel activity in lipid bilayers at cytoplasmic calcium concentrations of about 10 ⁻⁷ M to about 10 ⁻⁵ M, and 10 ⁻⁴ M (eg, 32.5 μM). Can be measured by its activity competing with inhibition of channel activity induced by known inhibitor peptides at cytoplasmic Ca ²⁺ concentrations below SEQ ID NO: 1).
[76] In no way is the present invention limited, and the inventors have constructed three peptides corresponding to analogs and derivatives of the human backbone DHPR 20-mer peptide sequence described as SEQ ID NO: 2 as defined herein. Peptides are detailed as follows.
[77] (i) SEQ ID NO: 8 corresponds to the 20-mer peptide of SEQ ID NO: 2, but serine ⁶⁸⁷ (residue 17 of SEQ ID NO: 2) is substituted with an alanine residue as follows.
[78] TSAQKAKAEERKRRKMARGL (SEQ ID NO: 8)
[79] (ii) SEQ ID NO: 9 corresponds to the 20-mer peptide of SEQ ID NO: 2, but arginine ⁶⁸⁸ (residue 18 of SEQ ID NO: 2) is substituted with D isomer of arginine as follows.
[80] TSAQKAKAEERKRRKMSRDGL (SEQ ID NO: 9)
[81] (iii) SEQ ID NO: 10 corresponds to the 20-mer peptide of SEQ ID NO: 2, but serine ⁶⁸⁷ (residue 17 of SEQ ID NO: 2) is substituted with an alanine residue and arginine ⁶⁸⁸ (SEQ ID NO: 2 Residue 18) is substituted with D isomer of arginine.
[82] TSAQKAKAERKRRKMARDGL (SEQ ID NO: 10)
[83] As used herein, the term “contacting”, which can mean a cardiac RyR2 channel having a basic peptide fragment of a DHPR polypeptide, does not necessarily require the actual binding of the channel to the peptide, but the peptide is to be brought into close physical association with the channel. It means to bring. In the practice of the present invention, although the DHPR peptide may bind to RyR2 channels, such binding is not an essential feature of the present invention. Because all that is required is modified channel activity. In this respect, the object of the present invention is not to obtain binding to the cardiac RyR2 polypeptide, but to regulate the activity of the RyR2 channel. One skilled in the art knows that binding and activity are not necessarily equivalent because the DHPR peptide can bind to any of a number of different sites on the RyR2 polypeptide without necessarily modifying the activity of the RyR2 channel.
[84] Preferably, the peptide is in contact with the cytoplasmic surface of the RyR2 channel.
[85] Preferably, the homologue of any one of SEQ ID NOs: 1-7 or any one of SEQ ID NOs: 1-7, for example, any one of SEQ ID NOs: 8-10, while carrying out the invention. , Analogs, or derivatives bind to a portion of the RyR2 polypeptide of the RyR2 channel. Without being limited to any theory or mode of action, the peptide (or homologue, analog, or derivative thereof) used in the practice of the present invention is one or more negative of the RyR2 polypeptide in the channel, such as, for example, an acidic residue in the amino acid sequence. By binding to the charged residues can take stereoconfiguration to access the RyR2 channel.
[86] FRAEKTYAVKAGRWYFEFEAVTSGDMRVGWSRPGCQP (SEQ ID NO: 13).
[87] As already discussed, in order to measure the activity of cardiac RyR2 calcium channels, it is not enough to simply measure the binding of peptides (or lysine in this matter) with channels or RyR2 polypeptides. However, it can, of course, form an aid for measuring modified channel activity. Preferred means for measuring channel activity is selected from the group consisting of the following (i)-(iv).
[88] (i) for example Ahern et al., 1994 FEBS Lett. 352: 369-374, Lu et al., 1994 J. Biol. Chem. 269: 6511-6516, Raver et al. Lipids using a technology-approved process, such as those described by Laver et al., 1995 J. Membr. Biol. 147: 7-22, or Dulhunty et al., 1999 homology. Recording of single or multiple RyR2 channel openings in the bilayer;
[89] (ii) for example with those described by El Hayek et al., 1995 homology, Gurolla et al., 1999 homology, or Dulhunty et al., 1999 homology. Measuring calcium release from SR vesicles using a technology-approved procedure, such as;
[90] (iii) measurement of cardiac function such as, for example, by measuring cardiac contractions according to Zaloga et al., 1997; And
[91] (iv) measuring vascular tension of the thoracic aortic annulus isolated after peptide administration using any technique-approved method of measuring vascular tension
[92] One skilled in the art can readily determine cardiac function by measuring the concentration dependence of peptide administration on one or more parameters selected from the group consisting of contractility, left ventricular systolic pressure, and heart rate as assessed by dP / dtmax or -dP / dtmax values. I know it is. In addition, ventricular fibrillation or other cardiac arrhythmias can be measured to quantify the side effects of the peptide.
[93] In assays for enhanced cardiac RyR2 channel activity, an enhanced channel opening probability (Po) is detected. Higher channel opening probabilities result in enhanced calcium outflow or release from SR, including SR vesicles, and enhanced cardiac contractility, and reduced relaxation. In addition, vascular tension can be enhanced.
[94] In contrast, inhibitors of cardiac RyR2 channel activity will reduce channel open probability, reduce calcium release from SR and reduce cardiac contractility. In addition, vascular tension can be reduced.
[95] Further methods of measuring modified cardiac RyR2 channel activity are not excluded.
[96] In regulating cardiac RYR channel activity, the efficacy of any one of SEQ ID NOs: 1-7 or homologues, analogs or derivatives thereof (such as SEQ ID NOs: 8-10), in particular SEQ ID NOs: 2, And the utility of such sequences as reagents used in the screening of compounds that share functional similarity. Such reagents enable high-throughput screening assays in which thousands of compounds can be screened quickly. Peptide mimetics that potentially have regulatory activity described herein can be tested for their ability to modulate cardiac RyR2 channel activity with isolated cardiac RyR2 receptors in lipid bilayers or in other suitable assay formats.
[97] Accordingly, a second aspect of the invention provides a method for identifying a peptide or non-peptide modulator of cardiac RyR2 calcium channel, the method
[98] (i) incubating the amount of a dihydropyridine receptor polypeptide or a homologue, analog or derivative thereof that modulates cardiac RyR2 channel activity in the presence of a functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be modulated, Measuring the activity of the channel;
[99] (ii) incubating the candidate peptide or non-peptide compound in the presence of the functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be regulated by the dihydropyridine receptor polypeptide or homologue, analog or derivative thereof, Measuring the activity of the channel; And
[100] (iii) comparing the activity in (i) and (ii)
[101] It includes.
[102] Preferably, said fragment comprises at least five consecutive amino acids of the peptide sequence of SEQ ID NO: 1.
[103] Preferably, peptides are selected that have a similar or enhanced channel activity control to the homologs, analogs or derivatives of SEQ ID NO: 1 or SEQ ID NO: 1. Such peptides can be detected by similar or enhanced regulation of the channel activity detected in (ii) as compared to (i) above.
[104] For example, a fixed amount of SEQ ID NO: 1 or a homologue, analog or derivative thereof that modulates cardiac RyR2 channel activity can be added to the functional receptor. Next, the reaction mixture is incubated under suitable conditions in which activity can be controlled and the activity of the channel is measured. In parallel experiments the candidate peptide or non-peptide compound is incubated with the cardiac channel under conditions permitting the modulation of activity in the presence of SEQ ID NO: 1 and the channel activity of this test sample is SEQ ID NO: 1 or its homologues. , With respect to the activity of the analog or derivative. Peptides or non-peptide compounds with similar or enhanced regulatory activity compared to SEQ ID NO: 1 or homologues, analogs or derivatives thereof may be selected.
[105] In another embodiment, this aspect of the invention provides a method of identifying a peptide or non-peptide modulator of a cardiac RyR2 calcium channel, the method comprising
[106] (i) incubating the amount of a dihydropyridine receptor polypeptide or a homologue, analog or derivative thereof that modulates cardiac RyR2 channel activity in the presence of a functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be modulated, Measuring the activity of the channel;
[107] (ii) the candidate peptide or non-peptide compound and the cardiac RyR2 calcium channel in the presence of a functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be modulated by the dihydropyridine receptor polypeptide or homolog, analog or derivative thereof. Incubating the amount of said dihydropyridine receptor polypeptide or homologue, analog or derivative thereof that modulates activity and measuring activity of the channel; And
[108] (iii) comparing the activity in (i) and (ii)
[109] Preferably, said fragment comprises at least five consecutive amino acids of the peptide sequence of SEQ ID NO: 1.
[110] In the most preferred embodiment of these embodiments of the invention, said SEQ ID NO: 1 peptide or homologue or derivative thereof is selected from any one or more of SEQ ID NOs: 2-10.
[111] Preferably, peptides or non-peptide mimetics and the like that are similar or have enhanced channel activity control to homologs, analogs or derivatives of SEQ ID NO: 1 or SEQ ID NO: 1 are selected. Such peptide or non-peptide compounds may be detected by similar or enhanced modulation of the channel activity detected in (ii) as compared to (i) above.
[112] For example, a fixed amount of a homologue, analog or derivative of SEQ ID NO: 1 or SEQ ID NO: 1 that modulates cardiac RyR2 channel activity can be added to the functional receptor under conditions that permit regulation to occur. The activity of the channel in the presence or absence of the candidate peptide is measured and the channel activity of the samples is compared. Peptides or non-peptide compounds that modulate the effect of SEQ ID NO: 1, or homologues, analogs or derivatives thereof on cardiac RyR2 calcium channel activity can be selected.
[113] Any conventional assay format that relies on the regulation of cardiac RyR2 channel activity is suitable for this purpose. Samples to be tested in the preferred assay format are Ry vesicles or dispedic muscle cells with RyR2, or functional cardiac RyR2 calcium channels, reconstituted in planar lipid bilayers. Using only routine experimentation, one skilled in the art can determine whether a particular candidate peptide, or non-peptide compound, modulates the activity of cardiac calcium channels.
[114] The present invention provides rapid high-throughput screens that allow some non-specificity and / or smaller scale functional screens with higher specificity, and / or quantitative kinetic studies to elucidate the chemical structure / function relationship of cardiac RyR2 channels, Consideration is given, for example, to the determination of peptide or non-peptide compounds that are agonists or antagonists of cardiac RyR2 calcium channel function, or the elucidation of docking site (s) of such compounds in the channel.
[115] Preferably, the present invention
[116] (i) identifying candidate agonists and antagonists of cardiac RyR2 calcium channel;
[117] (ii) determining whether the compounds of step (i) actually activate or inhibit the activity of the cardiac RyR2 channel;
[118] (iii) determining whether the compounds of step (ii) have a higher binding affinity for the cardiac RyR2 calcium channel than any of SEQ ID NOs: 1 to 10; And
[119] (iv) optionally, measuring the site of interaction between the compounds of step (iii) and the cardiac RyR2 calcium channel
[120] Consider the process, including.
[121] Rapid high-throughput screens for identifying candidate agonists and antagonists of cardiac RyR2 calcium channels are preferably cardiac RyR2 calcium channels expressed in microsomal preparations of cardiac muscle, or otherwise in CHO cells or other suitable cell-based assay systems. Is done using Such high-throughput screens facilitate the screening of multiple compounds incubated with microsomal preparations or injected into or incubated with transfect cells expressing RyR2 channels. In addition, high-throughput screens facilitate the screening of multiple peptides expressed from libraries transfected with cells expressing RyR2 channels.
[122] Alternatively, or in addition, the candidate agonist and antagonist molecules bind the cardiac RyR2 protein to a support, such as a plurality of polymerizable pins, and contact the polypeptides on the plurality of pins with the candidate agonist and / or antagonist molecules for screening. Confirmed by The molecules to be screened can be labeled with isotopes so that binding can be detected immediately. Alternatively, the compound to be screened can be bound to a solid support, such as a plurality of pins, that is reacted with a RyR2 polypeptide. Binding can be measured again, for example, by isotopic labels, or by antibody detection, or by the use of other reporting agents.
[123] The binding affinity of a particular chemical compound to the cardiac RyR2 calcium channel can be measured by any assay known to those of skill in the art useful for measuring kinetic parameters of protein-ligand interactions. Preferably, binding assays such as surface plasmon resonance are used. Surface plasmon resonance of the protein can be measured using, for example, a Biacore ™ analyzer. As is known to those skilled in the art, this method provides data of on and off ratio measurements for the binding of the ligand to the protein of interest.
[124] In order to screen multiple candidate compounds, the compounds may be attached to a plurality of polymerizable pins or supports.
[125] In order to determine the interaction site (s) between the candidate compound and the cardiac RyR2 calcium channel, the binding of various mutant RyR2 polypeptides having one or more sites deleted in the autologous protein or substituted with variant amino acid sequences is determined and said compound The binding of the wild type or non-mutated RyR2 protein can be compared. Once again, surface plasmon resonance can be used to facilitate comparison of binding affinity. Although enhanced binding affinity is used, data on interaction sites that provide stronger agonist / antagonist activity is used to facilitate the rational design of drugs that bind to such sites.
[126] Compounds detected using this screening procedure can ultimately be used, for example, in the treatment of cardiac dysfunction.
[127] In other embodiments, agonist and / or antagonist compounds are identified using reasonable drug design by identifying compounds that bind to or associate with the three-dimensional structure of the cardiac RyR2 calcium channel. The present invention clearly contemplates any synthetic compound that binds to a calcium channel derived from the three-dimensional structure of the cardiac RyR2 calcium channel and activates or inhibits cardiac RyR2 calcium channel activity.
[128] The observation that the open probability of the cardiac RyR2 channel is modified by incubation with SEQ ID NO: 1 or its homologues, analogs or derivatives may be useful in establishing or measuring the pore structure and regulatory mechanisms of the cardiac RyR2 channel in vitro and in vivo. Establish the usefulness of such sequences. More specifically, the correlation between the binding of the peptide and RyR2 and the high open probability of the channel and the correlation between the non-specific binding of the peptide and the low open probability at negatively charged residues in the channel pores is open based on peptide binding studies. Enables prediction of probability
[129] Accordingly, a third aspect of the present invention provides a method for measuring whether a cardiac RyR2 channel is open or has a high channel open probability, wherein the method provides a cardiac RyR2 channel under sufficient time and conditions to allow binding to RyR2 to occur. Contacting an amount of a fragment of a dihydropyridine receptor (DHPR) polypeptide or a homologue, analog or derivative thereof, and measuring the binding of the peptide to RyR2, wherein the binding of the peptide to RyR2 is a high channel Non-specific peptide bonds of the peptide and channel pores show an open probability and low channel open probability.
[130] Accordingly, a third aspect of the present invention provides a method for measuring whether a cardiac RyR2 channel is open or has a high channel open probability, wherein the method provides a cardiac RyR2 channel under a time and condition sufficient to result in binding to RyR2. Contacting the dihydropyridine receptor (DHPR) polypeptide or a homologue, analog or derivative thereof and measuring the binding of the peptide to RyR2, wherein the binding of the peptide to RyR2 results in a high channel open probability. Non-specific binding of peptides and channel pores shows low channel open probability.
[131] Preferably, said fragment is substantially a peptide as defined in any one or more of SEQ ID NO: 1 to 10.
[132] Peptide binding is any method known to those skilled in the art, for example, using a radioactive label or fluorescently labeled peptide, or a peptide labeled with a reporter molecule, to determine the amount of label or reporter molecule bound to a channel at a particular concentration of peptide. Can be measured by Preferred reporter molecules for this purpose are small molecules, eg photoactivable compounds, which do not interfere with the peptide's ability to bind channels.
[133] Alternatively, peptide binding can be measured indirectly by measuring the activity of the channel of calcium release through the channel. As exemplified herein, at concentrations between about 1 nM to about 10 μM peptides result in a high channel open probability, while at higher concentrations the peptide shows a low channel open probability, especially for the channels of the lipid bilayer.
[134] A fourth aspect of the invention provides a method of treating cardiac dysfunction in a human or animal subject, the method comprising dihydropyridine receptor (DHPR) polypeptide or derivative thereof, at a time and under conditions sufficient to result in enhanced heart contraction, Administering an effective amount of a fragment of the homologue or analog, thereby correcting for cardiac dysfunction.
[135] Preferably, said fragment comprises substantially at least five consecutive amino acids of the peptide as defined in any one or more of SEQ ID NO: 1 to 10.
[136] By "cardiac dysfunction" is meant a condition involving impaired myocardial contraction, for example, where Ca ²⁺ sensitivity of muscle filaments is reduced or, for example, degeneration or rupture of calcium synapses, degeneration of RyR2, or of DHPR There is a degeneration of calcium signaling, such as by degeneration. The state of cardiac dysfunction contemplated herein that can be treated according to the present invention is not limited, but myocardial contraction, ischemic heart disease, systemic inflammatory conditions such as sepsis, cardiac hypertrophy (calcium overload), arrhythmic left ventricular dysplasia types Cardiomyopathy, such as -2 (ARVD2), and drugs (eg, cocaine) -induced cardiomyopathy, infarction, rhythm disorders, congestive heart failure, or heart attacks.
[137] "Effective amount" means an amount of peptide sufficient to reduce or reverse the progression of dysfunction.
[138] For this aspect of the invention, the beneficial or preferred clinical outcome is not limited, but detectable or not, alleviation of symptoms, reduction of disease range, stabilization of disease state, delay or slowing disease progression, improvement of disease state or Temporary relief, and relief (either partially or in full). "Treatment" also includes prolonged survival compared to the expected survival of the untreated subject.
[139] "Temporary alleviation" of a disease means that the extent and / or undesirable clinical findings of the disease state are reduced by treatment and / or the time course of progression is slowed or lengthened.
[140] With regard to prevention, "subject" is not limited, but individuals within the general population of about 40 years of age or older, especially respiratory distress, such as cardiac hypertrophy, cardiomyopathy, heart attack, hypertension, renal failure, vascular hypertension, pulmonary edema or cystic fibrosis, chronic Asthma and predisposition to develop tuberculosis or individuals with such a history. Suitable subjects also include organ transplant patients.
[141] In a fifth aspect of the invention, a peptide set forth in any one of SEQ ID NOs: 1-10 or homologues, analogs or derivatives thereof for modifying defective calcium signaling by modifying the activity of the cardiac lianodyne calcium channel The use of a fragment of a dihydropyridine receptor polypeptide comprising at least five consecutive amino acid residues of is provided.
[142] Preferably, the defective calcium signaling comprises chronic hypertrophy, dilatation cardiomyopathy or heart failure.
[143] In a sixth aspect of the invention, in the manufacture of a medicament for treating cardiac dysfunction in a human or animal subject, at least five of the peptides or homologs, analogs or derivatives thereof set forth in any one of SEQ ID NOs: 1 to 10 The use of fragments of dihydropyridine receptor polypeptides comprising contiguous amino acid residues is provided.
[144] The present invention provides for modifying the activity of the cardiac RyR2 calcium channel, thereby modifying defective calcium signaling that causes chronic hypertrophy or swelling cardiomyopathy or even heart failure in chronic untreated animals or human subjects. The use of the peptides set forth in any one of 10 or homologues, analogs or derivatives thereof is provided.
[145] Preferably, a peptide or a homologue, analogue or derivative during systolic further enhancing the contractile force of increasing the intracellular calcium concentration (i.e., [Ca ^2+] i), for a further expander [Ca ^2+] i It is administered at a dose that can reduce. Preferably, the peptide or homologue, analog or derivative thereof is at least about 3% or 5 of systolic [Ca ²⁺ ] i compared to systolic [Ca ²⁺ ] i measured in the absence of peptide in standard ex vivo calcium-sensitized assays. Causes an increase in%. Preferably, the peptide or homologue, analog or derivative thereof is at least about 3% or 5 of the diastolic [Ca ²⁺ ] i compared to the diastolic [Ca ²⁺ ] i measured in the absence of the peptide in a standard ex vivo calcium-sensitized assay Causes a decrease in%. More preferably, up to at least about 10% or 15%, even more preferred, as compared to systolic [Ca ²⁺ ] i or diastolic [Ca ²⁺ ] i respectively measured in the absence of peptides in such standard ex vivo calcium-sensitized assays. Such that systolic [Ca ²⁺ ] i is increased, or diastolic [Ca ²⁺ ] i is reduced by at least about 20%, 25%, 30%, 40% or 50%.
[146] Even more preferably, the administered peptide, or homologue, analog or derivative thereof, improves cardiac contractile efficacy. Preferably, the cardiac contraction is enhanced by causing an increase in at least about 5% or 10% of the full load-filling ejection workload (PRSW) within 0.5-1.0 hours after administration. More preferably, heart contractions are enhanced by about 15%, 20%, 30%, 40%, 50%, 55%, 60% or 70% as measured by the increase in PRSW in heart failure patients compared to healthy individuals. .
[147] For example, the peptide, or homologue, analog or derivative thereof, may be administered immediately to a patient suffering from or suffering from congestive heart failure or cardiac shock. Preferably, such immediate administration is within about 1, 2, 4, 8, 12 or 24 hours after the patient suffers from heart failure such as congestive heart failure or cardiac shock, or from 1 day to about 2 or 3 weeks, It will involve the administration of a suitable dose of peptide to enhance RyR2 calcium channel activity.
[148] In addition, relatively long-term administration of the peptide, or homologue, analog or derivative thereof, at a dose suitable to activate RyR2 calcium channel activity would be advantageous in providing the patient with increased exercise tolerance and functional capacity after suffering from chronic heart failure. will be. For example, the peptide may be present for at least 2, 4, 6, 8, 12, 16, 18, 20 or 24 weeks, or even longer, for example 6 months, 1 year, 3 years or after suffering from heart failure. During this period, the patient may be administered regularly to promote the enhancement of functional ability. Oral dose formulations would be preferred for such long term administration.
[149] The administration of peptides, or homologues, analogs or derivatives thereof, at a dose that inhibits cardiac RyR2 calcium channel activity in human or animal subjects is also not excluded and may be suitable, for example, when temporary relaxation of heart tissue is required.
[150] Toxicity and therapeutic efficacy of peptides, homologues, analogs or derivatives are treated by standard pharmaceutical procedures in cell cultures or experimental animals, for example, LD ₅₀ (50% lethal dose of the population) and ED ₅₀ (50% of the population). Effective amount) can be measured. The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio of LD ₅₀ / ED ₅₀ . Preference is given to amino acid sequences set forth in any one of SEQ ID NOs: 1-7, or homologues, analogs, or derivatives having a high therapeutic index.
[151] Peptides, homologues, analogs, or derivatives that exhibit toxic side effects or have high LD ₅₀ values are less preferred, but such peptides can be used in conjunction with delivery systems that target such compounds against diseased tissue sites, thereby resulting in healthy Minimize potential damage to tissues.
[152] Data obtained from cell based assays and animal studies can be used to formulate a range of dosages of the peptides used in humans. Animal models of cardiac hypertrophy described by Grant et al. (Submitted US Pat. No. 6,201,165, 2001.3.13) are particularly useful for this purpose. Preferably, the doses of peptides, homologues, analogs or derivatives are placed within a range of concentrations which, after administration by a particular route, result in blood levels that are consistent with ED ₅₀ and have little toxicity. The dosage may vary within this range depending upon the formulation and route of administration. In addition, the dose may vary depending on factors such as the individual's disease, the severity of the disease, age, sex and weight.
[153] For any peptide, homologue, analog, or derivative used in the methods of the invention, the therapeutically effective amount can be initially estimated from cell based assays or animal models. For example, an effective amount may be achieved to achieve a range of plasma concentrations in blood, including an IC ₅₀ (i.e., a concentration of peptide or non-peptide compound that achieves maximum-half inhibition of symptoms) as measured in cell based assays and / or whole animals. It can be formulated in animal models. Such information can be used to more accurately measure useful doses in humans.
[154] In addition, suitable doses of peptides, or homologues, analogs or derivatives thereof, may cause heart failure in animal models by rapid ventricular modulation over long periods of time, followed by injecting different concentrations of peptides into the left atrium at a rate of about 3.3 mL / min. , And then by recording the pressure-size relationship and arterial pressure response to the peptide. In addition, control experiments using known calcium sensitizers can be carried out, for example those described by Marban (US Pat. No. 6,191,136, 2001.2.20). In addition, cardiac oxygen consumption can be measured.
[155] Another aspect of the invention relates to a pharmaceutical composition comprising a fragment of a dihydropyridine receptor polypeptide with one or more pharmaceutically acceptable carriers and / or diluents, wherein the peptide is any one of SEQ ID NOs: 1-10. At least about 5 consecutive amino acid residues of a peptide set forth in one, or homologues, analogs or derivatives thereof.
[156] The therapeutic efficacy of the substances detected by the methods of the present invention in the treatment of cardiac dysfunction can be achieved by those skilled in the art using known principles of diagnosis and treatment.
[157] The therapeutic composition must be sterile and stable under the conditions of manufacture and storage. Peptides may be formulated in solution, microemulsions, liposomes, or other ordered structures suitable for high drug concentrations. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (eg glycerol, propylene glycol, liquid polyethylene glycols, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. In many cases, it will be preferable to include, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
[158] Enhanced absorption can be achieved by conjugation of a lipid or liposaccharide moiety with a peptide, or homologue, analog or derivative thereof.
[159] Prolonged absorption of the injectable composition may be brought about by including in the composition an agent that delays absorption, for example, monostearate salt or gelatin. Furthermore, the compounds may be administered in a timed release formulation, for example in a composition comprising a sustained release or controlled release polymer comprising preferably hydrophobic and / or amphoteric compounds. Like controlled release formulations including implants and microencapsulated delivery systems, peptides can be prepared with a carrier that protects the compound against rapid release. Biodegradable biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polytaxes, polyglycol copolymers (PLG). Methods of preparing such formulations are generally known to those skilled in the art.
[160] For example, suitable controlled release delivery ampoules can be prepared by dispersing a peptide, homologue, analog or derivative in a bioerodible biodegradable poly (ε-caprolactone) polymer matrix in the melting step, provided that the peptide or protein drug Silver is in the form of a glassy matrix having a glass transition temperature higher than the melting point of the poly (ε-caprolactone) polymer, for example as described by Wang et al., USSN 6,187,330. For example, an aqueous solution of trehalose, melezitose, lactose, maltose, cellobiose, melibiose, or raffinose) is dispersed onto the glassy matrix produced by lyophilization.
[161] Sterile injectable solutions can be prepared by mixing the peptides, homologues, analogs or derivatives as necessary into a required amount of a suitable solvent having one or a combination of ingredients described above, followed by filtered sterilization. Generally, dispersions are prepared by mixing the active peptide or non-peptide compound with a sterile excipient containing a basic dispersion medium and the required other ingredients from those described above. In the case of sterile flour for the preparation of sterile injectable solutions, preferred methods of preparation are vacuum drying and lyophilization, which provide the powder of the active ingredient and any further desired ingredients from already sterile-filtered solutions.
[162] Preferably, the peptides, or homologues, analogs or derivatives thereof of the present invention may be formulated to prolong their half-life after administration, especially in formulations for the treatment of chronic abnormalities. Methods of extending the half-life of an active peptide compound include eliminating sites for known proteases by direct modifications that reduce their proteolysis, such as crosslinking or amino acid substitutions. Alternatively, the half-life of any active ingredient can be extended by encapsulating it in a suitable formulation, eg, a sustained release formulation. Depending on the route of administration, the peptides, homologues, analogs or derivatives may be coated with a material that protects it from enzymes, acids and other natural actions that can lead to inactivation thereof.
[163] For example, peptides, homologues, analogs or derivatives can be administered to a subject in a suitable carrier administered with an enzyme inhibitor or as a diluent or in a suitable carrier such as liposomes. Pharmaceutically acceptable diluents include saline and aqueous buffers. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluoro-phosphate (DEP) and trasylol. Liposomes include water / milk / water emulsions and conventional liposomes.
[164] Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
[165] In addition, the present invention is described with reference to the following non-limiting examples.
[166] Example 1
[167] 20-mer Peptides Modulate Cardiac RyR2 Calcium Channel Activity
[168] Materials and methods
[169] material:
[170] Chemical and biochemical materials were obtained from Sigma-Aldrich (Australia Castle Hill). DHPR II-III loop peptide (SEQ ID NO: 1-7) was synthesized using an Applied Biosystem 430A Peptide Synthesizer and purified to ≧ 98% using HPLC and mass spectrometry and NMR. Peptides were prepared as ˜2 mM stock solution in H ₂ O and frozen by 20 μl aliquots. The exact stock solution concentration was measured by Auspep Pty Ltd and subsequent standard PTC (phenylthiocarbamyl) protocol using acid hydrolysis and analyzed by reverse phase HPLC.
[171] Peptides:
[172] The specific peptides used in the study were:
[173] 1.20-mer peptide (SEQ ID NO: 2) of II-II cytoplasmic loop of DHPR:
[174] Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser Lys Gly Leu
[175] 2. Peptide NB (N-terminal portion of B segment of II-III loop; Hamilton and Ianuzzo, 1991; SEQ ID NO: 11):
[176] Gly Leu Pro Asp Lys Thr Glu Glu Glu Lys Ser Val Met Ala Lys Lys Leu Glu Gln Lys
[177] 3. Peptide AIS (scrambled 20-mer peptide; SEQ ID NO: 12):
[178] Thr Arg Lys Ser Arg Leu Ala Arg Gly Gln Lys Ala Lys Ala Lys Ser Glu Met Arg Glu
[179] SR Parcel Manufacturing:
[180] SR vesicles were isolated from sheep hearts as described by Raver et al. (1995 J. Membr. Biol. 147: 7-22).
[181] Lipid bilayer:
[182] The experiment was carried out at 20 ° C. to 25 ° C. in accordance with Ahern et al. (1994, FEBS Lett. 352: 369-374) and Raver et al. (1995 J. Membr. Biol. 147: 7-22). Bilayers are ˜100 μm diameter on the wall of 1.0 ml Delrin Cup (Cadillac Plastics, Australia) from phosphatidylethanolamine, phosphatidylserine and phosphatidylcholine (5: 3: 2 w / w / w) (Avanti Polar Lipid, Alabama) Formed across the gap. Terminal cysteine (TC) vesicles (final concentration 10 μg / ml) and drug were added to the cytoplasmic (ie cis) chamber. Bilayer potential was adjusted and single channel activity was recorded using an Axopatch 200A amplifier (Axon Instruments, Poster City, CA). For the experiment, the sheath chamber was fixed to the ground and the voltage of the lumen (ie trans) chamber was adjusted. Bilayer translocation is expressed as V _cis -V _trans (ie, V _cytoplasm -V _lumen ) in a conventional manner.
[183] Bilayer solution:
[184] Bilayers were prepared as described above, 230 mM Cs methanesulfonate (MS), 20 mM CsCl, 1 mM CaCl ₂ and 10 mM N-tris [hydroxymethyl] methyl-2-aminoethanesulfonic acid (TES with CsOH, pH 7.4) The vesicles were mixed in a bilayer using a cis solution containing and a trans solution containing 30 mM Cs MS, 20 mM CsCl, 1 mM CaCl ₂ and 10 mM TES (pH 7.4).
[185] The current was filtered at 1kHz (8-pole lowpass vessel, -3dB) and digitalized at 5kHz. Analysis of single channel recordings (using channel 2 developed by P. Gage and M. Smith) shows channel open probability (Po), event frequency (Fo), open time, The average current (I ′) was provided as well as the close time and average open or close time (To or Tc). The event discrimination device was set above the baseline noise at ˜20% of the maximum current rather than the usual 50%, so the opening up to subconductance and the maximum conductance level were included in the analysis. Channel activity was analyzed over two 30 second periods of continuous activity at +40 mV and two 30 second periods of continuous activity at -40 mV.
[186] Statistical analysis:
[187] Mean data are given as mean ± SEM. The significance of the difference between control and test values was tested using either one-sided or two-sided Student's T-test as appropriate for independent or paired data. Differences were considered significant when P ≦ 0.05.
[188] Example 2
[189] 20-mer Peptides Modulate Cardiac RyR2 Calcium Channel Activity
[190] result
[191] When 20-mer peptide (SEQ ID NO: 2) was added to the cytosolic (cis) side of the channel at a concentration of 10-7M cis Ca ²⁺ , it showed an increase in RyR2 activity from cardiac muscle. Single channels were identified as RyRs by Cs + conductance of ˜450 pA at a bilayer potential of +40 mV or -40 mV, and by the ability of 30 μM ruthenium red to block the channel at the end of the experiment.
[192] Records from one experiment where cardiac RyRs were strongly activated by 20-mer peptide (SEQ ID NO: 2) are shown in FIGS. 2 (-40 mV) and 3 (+40 mV). Channel activity prior to peptide addition consisted of short intermittent openings (FIG. 2 panel A; FIG. 3 panel A). Within 10 seconds of adding 65 nM peptide (SEQ ID NO: 2) the channel opening increased at -40 mV.
[193] An increase in the frequency of events, the appearance of very long openings, was accompanied by the opening of the second channel in the bilayer (FIG. 2 panel B). RyR2 channel activity at -40 mV dropped slightly when peptide concentration increased to 6.5 μm SEQ ID NO: 2, but the activity of the second channel became more apparent. As shown in panel C of FIG. 2, the channel shows a high open probability (Po), especially in the 65 nM peptide (dominant current level, O, expected when the channel is sufficiently open).
[194] Recordings indicate that the increase in single channel activity was not associated with any change in single channel conductance.
[195] In addition, channel activity was increased in 65 nM 20-mer peptide (SEQ ID NO: 2) when the bilayer potential was +40 mV (FIG. 3 panel B). However, the increase in channel activity was less than that observed for the same channel at −40 mV (FIG. 2 panel B).
[196] At -40 mV bilayer potential, channel activity increased at higher peptide concentrations, while at +40 mV channel openings began to decrease at concentrations above about 100 nM peptide, with only a few short channel openings observed at 10 μM peptide due to low conductance levels. (Figure 3 Panel C). Although the present invention is not limited to any one theory or mode of action, a decrease in activity at +40 mV (where channel opening is largely due to submaximal conductance) is a low affinity site other than the site to which peptide binds during channel activation. It is considered that the peptide (SEQ ID NO: 2) binds to the bond. These low affinity sites will be in amido channel pores.
[197] Similar activation and inhibition of cardiac RyR2 channels in lipid bilayers is obtained in 8 of 8 bilayer samples. Since most bilayers contained more than one channel, no single channel analysis was performed. All samples had a higher frequency opening at +40 mV after addition of peptide (SEQ ID NO: 2) to the sheath chamber. In addition, at a potential of -40 mV in the presence of the peptide, an extended channel opening occurred, compared to that detected in the absence of peptide at 10-7M cis Ca ²⁺ .
[198] The average current (ie, the mean of all data points in two 30-second recordings, at each potential and each peptide concentration, divided by the number of channels shown in the recordings) provided a measure of channel activity. Mean normalized mean current is shown in FIG. 4 as a function of peptide concentration. The integer I'p / I'c is the ratio of the average current in the presence of the peptide to the average current before adding the peptide to the chamber. A significant increase (˜2 fold) in mean current was detected in the 10 nM peptide (SEQ ID NO: 2) at bilayer potential of −40 mV or +40 mV. At -40 mV, the average current increased by more than four times in 50 μM peptide (SEQ ID NO: 2). In contrast, the average current normalized at +40 mV was doubled for 10 nM peptides (SEQ ID NO: 2) and continued to rise to about 10 μM peptides, then dramatic at higher peptide concentrations (ie, at about 10 μM to 50 μM peptides). Fell into.
[199] In addition, the specificity of activation of the cardiac RyR2 channel by 20-mer peptide (SEQ ID NO: 2) was tested. Modified channel activity was observed at either +40 mV or -40 mV bilayer potential in 1 μM cis peptide NB (SEQ ID NO: 8) or 10 μM cis peptide NB (n = 3; FIG. 4). When a scrambled sequence (ie peptide A1S; SEQ ID NO: 9), having the same isoelectric point but a non-homologous sequence as the 20-mer peptide tested, was present at a higher concentration (ie 1 μM cis peptide or 10 μM cis peptide) In two of the remaining two bilayers, cardiac RyR2 channel activity was reduced (FIG. 4).
[200] The data strongly supports that activation by the 20-mer peptide (SEQ ID NO: 2) reflects binding to cardiac RyR2 channels.
[201] While not limiting the invention in any way, the ability of 20-mer peptide (SEQ ID NO: 2) and peptide A1S to inhibit cardiac RyR activity at higher concentrations unexpectedly results in pores in cardiac and skeletal RyRs or Vestibular suggests that it contains a significant number of negative sites that can interact with the positively charged residues of the peptide. The fact that inhibition continues with peptide A1S in the absence of activation provides further evidence that activation and inhibition depend on a 20-mer peptide (SEQ ID NO: 2) that binds to two separate sites on the RyR2 channel.
[202] Example 3
[203] Functional Analysis of DHPR 20-mer Fragment Derivatives and Analogs
[204] Materials and methods
[205] Peptides:
[206] Four peptides were tested in this series of experiments. These are as follows:
[207] (i) native DHPR 20-mer peptide (SEQ ID NO: 2);
[208] (ii) SEQ ID NO: 8 wherein Ser ⁶⁸⁷ (residue 17) of SEQ ID NO: 2 peptide was replaced with an alanine residue;
[209] (iii) SEQ ID NO: 9, wherein Arg ⁶⁸⁸ (residue 18) of SEQ ID NO: 2 peptide is replaced with the D isomer;
[210] (iv) SEQ ID NO: 10 wherein Ser ⁶⁸⁷ of the SEQ ID NO: 2 peptide is mutated to alanine and Arg ⁶⁸⁸ is replaced by the D isomer
[211] Measurement of Ca ²⁺ Release from Cardiac SR:
[212] Cardiac SR vesicles (50 μg protein) were treated with 100 mM KH ₂ PO ₄ (pH = 7); 4 mM MgCl ₂ ; 1 mM Na ₂ ATP; To a cuvette was added a final volume of 2 ml in a solution containing 0.5 mM antipyrilazo III. Extravesicular [Ca ²⁺ ] was monitored at 710 nm using a Carry 50 or Carry 100 spectrometer. The same experiment at 790 nm did not show a change in OD, which is independent of the change in [Ca ²⁺ ], which would change the rate of Ca ²⁺ emission measured at 710 nm. Vesicles were loaded with Ca ²⁺ by adding 3 mM aliquots of 5 mM CaCl ₂ four times to a final concentration of 7.5 μΜ Ca ²⁺ . Next, Topsijin (200nM) was added to block SR Ca ²⁺ ATPase. Finally, peptides were added alone or in combination with 20 μΜ Ca ²⁺ or 2 mM caffeine. The Ca ²⁺ release rate was measured immediately before the addition of the activator in the presence of topsiazine, and the Ca ²⁺ initial release rate was measured immediately after the addition of the activator. Next, 5 μM of ruthenium red, a specific blocker of RyR activity, was added to ensure that Ca ²⁺ was released only through the RyR channel. At the end of the experiment, Ca ²⁺ ionopo A23187 (3 μg / ml) was added to determine the amount of Ca ²⁺ remaining in the SR vesicles. When Ca ²⁺ release was complete, the temporary retention of Ca ²⁺ following the addition of ionopo was a sign for the portion of the vesicle containing Ca ²⁺ that could not be released through the RyR channel (probably lacking the RyR channel). Parcels from longitudinal SR). The results indicated that only 10-20% of the cardiac SR preparations contained RyR regulated stores. The experiment was repeated for vesicles separated from three different sheep heart preparations.
[213] Single channel experiment:
[214] The Ca ²⁺ concentration was buffered at 100 nM in the cis solution and adjusted to 100 μM by adding CaCl ₂ to the cis solution in the absence of BAPTA.
[215] Example 4
[216] Functional Analysis of DHPR 20-mer Peptide Fragment Derivatives and Analogs
[217] result
[218] summary:
[219] The experiment of Example 4 involves testing all compounds for Ca ²⁺ release from cardiac SR vesicles. In addition, a single cardiac RyR channel was exposed to peptide SEQ ID NO: 9. All peptides Ca ^2+-activated Ca ²⁺ release or caffeine-was considerably increase the speed of the activated Ca ²⁺ release. Peptides SEQ ID NOs: 9 and 10 enhanced the rate of Ca ²⁺ release to the minimum in the absence of activated Ca ²⁺ or caffeine at high concentrations of> 30 μM, and also gave Ca ^{2+ -activated} Ca ²⁺ release and Both caffeine-activated Ca ²⁺ release was enhanced. Peptide SEQ ID NO: 9 enhanced cardiac RyR activity at low concentrations (1-10 nM) in lipid bilayer experiments, but blocked channel pores in a voltage- and Ca ²⁺ -dependent manner at +40 mV at high concentrations. Thus, under suitable physiological conditions, the dihydropyridine receptor fragment peptide can bind to cardiac Ca ²⁺ release channels to activate Ca ²⁺ release from cardiac SR.
[220] Effect of peptides on Ca ²⁺ release from cardiac SR:
[221] The ability of the peptides defined by SEQ ID NOs: 2, 8, 9 and 10 to release Ca ²⁺ from cardiac SR was measured in the absence of additional activating factors. Peptides were added to the extrafoveal solution and the initial rate of Ca ²⁺ release was measured immediately after peptide addition. Average data for four peptides are shown in FIG. 5 (small symbols). All peptides at concentrations of 30 μM and 50 μM showed a small increase in release rate.
[222] Ca ²⁺ - and tested the effect of the peptide to the activated Ca ²⁺ emission-activated Ca ²⁺ release and caffeine. Ca ²⁺ -activation is the main in vivo mechanism of RyR activation during cardiac contraction. Since the main effect of caffeine is to shift the Ca ²⁺ -activation curve towards much lower Ca ²⁺ concentrations, the Ca ^{2+ -activation} mechanism prevents Ca ^{2+ -activation} and caffeine-activated Ca ²⁺ release from SR vesicles. Brings in all. A stationary Ca ²⁺ concentration of ˜100 nM activates Ca ²⁺ release in the presence of caffeine. The initial Ca ²⁺ release rates induced by 20 μM Ca ²⁺ and 2 mM caffeine were similar, 10 μmol Ca ²⁺ per mg of SR protein per minute in these experiments. In addition, Ca ^2+-induced Ca ²⁺ release, and caffeine-induced was also similar to the effect of the peptide on Ca ²⁺ release, to be classified with the average data shown in Figure 5 the data obtained in two activation methods. Clearly, each of the four peptides can increase Ca ²⁺ / caffeine-activated Ca ²⁺ release from cardiac SR vesicles when added to extrafoveal solution. In all experiments, Ca ²⁺ release was terminated by the addition of ruthenium red, indicating that the release was through RyR channels. The maximum rate of Ca ²⁺ release for each of the four peptides was 2-2.5 times greater than the control and activated on 20-30 μM peptides. It was evident that the four peptides doubled in that the Ca ²⁺ release rate tended to drop at higher peptide concentrations.
[223] The peptides in both Ca ²⁺ release from the SR heart and Ca ²⁺ / caffeine - showed a similar deseo potential to promote active Ca ²⁺ release. Emissions from non-Ca ²⁺ / caffeine-activated channels are too small to detect differences between peptides. While not limiting the invention in any way, this similarity between the effects of the peptide on Ca ²⁺ / caffeine-activated Ca ²⁺ release is such that the RyR channel approaches maximum opening using only the activator and therefore It may reflect the fact that their capacity to be further activated by is limited.
[224] Effect of peptide SEQ ID NO: 9 on single cardiac RyR channel activity:
[225] The action of SEQ ID NO: 9 on the active single cardiac RyR channel of the lipid bilayer was tested. Peptides were initially added to the cytoplasmic (cis) side of the cardiac RyR channel with 100 μM cis Ca ²⁺ . The peptide failed to activate the channel (FIG. 6).
[226] The decrease in the activity of the cardiac RyR channel induced when peptide SEQ ID NO: 9 was added to the bilayer solution was greater at +40 mV than -40 mV, thus the voltage-dependent dependence of the backbone RyR channel by peptide SEQ ID NO: 2 ( Ie current-dependent blocking. The decrease in activity is consistent with the positive charge of the SEQ ID NO: 9 peptide entering the ion channel and associated with the negative charge in the pores. Blocking is enhanced when the current flows from the cis to the trans and the peptide is carried into the pore, but is partially reversed when the current flows from the trans to the cis and the peptide tends to be transported out of the pore.
[227] 100 nM peptide cis Ca ²⁺ concentrations buffered with 2 mM BAPTA were used. Strong activation of cardiac channels by peptide SEQ ID NO: 9 resulted in a 10-20 fold increase in relative mean current at both positive and negative potentials. There was a significant increase in activity with only 10 nM peptides and maximal activation was observed for 100 nM peptides. At higher peptide concentrations (1 and 10 μM) at +40 mV, the decrease in relative mean current was a sign of the residual blocking action of the peptide.
[228] The effect of this peptide on the mean single channel parameter of cardiac RyR was measured and the mean data is shown in FIG. 8. Peptides resulted in a ˜50-fold increase in open probability at −40 mV and a ˜10-fold increase in +40 mV. This increase in activity was due to an 8-fold increase in mean open time at both potentials, an 80 or 170-fold decrease in mean close time at +40 mV and -40 mV, respectively, and an increase in the corresponding event frequency. Thus, the main effect of peptides on channel gating is on mean close time.
[229] Thus, the DHPR II-III loop SEQ ID NO: 2 peptide can activate Ca ²⁺ release from cardiac RyR channels and cardiac SR vesicles. Not only does the natural peptide release Ca ²⁺ , but several other peptides with enhanced helix structure, preferably peptides containing RKRRK sequences, exhibit the same action on Ca ²⁺ release.
[230] Those skilled in the art will recognize that the invention described herein may embrace changes and modifications other than those specifically described. It should be understood that the present invention includes all such changes and modifications. In addition, the present invention includes, individually or collectively, all of the steps, features, compositions, and compounds mentioned or indicated herein, and any and all combinations of the steps or features, or any two or more thereof.
[231] The present invention is not to be limited in scope by the specific embodiments described herein, which are for illustration only. Functionally equivalent products, compositions and methods described herein are also clearly within the scope of the present invention.
[232] (references)
[233] Ahern, G. P., P. R. Junankar, and A. F. Dulhunty. 1994. FEBS Lett. 352: 369-374.
[234] Bhat, M. B., J. Zhao, H. Takeshima, and J. Ma. 1997. Biophys. J: 73: 1329-1336.
[235] Chaudhari, N. 1992. J Biol Chem 1992 Dec 25; 267 (36): 25636-9 267: 25636-25639.
[236] Cheng, H., W. J. Lederer, and M. B. Cannell. 1993. Science 262: 740-744.
[237] Devereux, J., Haeberli, P. and Smithies, O. 1984. Nucl. Acids Res. 12: 387-395.
[238] Drouet, B., L. Garcia, D. Simon-Chazottes, M. Mattei, J. Guenet, A. Schwarz, G. Varadi, and M. Pincon-Raymond. 1993. Mamm Genome 4: 499-503.
[239] Dulhunty, A. F., D. R. Laver, E. M. Gallant, M. G. Casarotto, S. M. Pace, and S. Curtis. 1999.
[240] Biophys. J: 77: 189-203.
[241] El-Hayek, R., B. Antoniu, J. Wang, S. L. Hamilton, and N. Ikemoto. 1995. J Biol. Chem. 270: 22116-22118.
[242] Gomez, A., H. Valdivia, H. Cheng, M. Lederer, L. Santana, M. Cannell, S. McCune, R. Altschuld, and W. Lederer. 1997. Science 276: 755-756.
[243] Gurrola, G. B., C. Arevalo, R. Sreekumar, A. J. Lokuta, J. W. Walker, and H. H. Valdivia. 1999.J. BioLChem. 274: 7879-7886.
[244] Laver, D.R., L. D. Roden, G. P. Ahern, K. R. Eager, P. R. Junankar, and A. F. Dulhunty. 1995. J. Membr. Biol. 147: 7-22.
[245] Lu, X., L. Xu, and G. Meissner. 1994. J. Biol. Chem. 269: 6511-6516.
[246] McCall, E., L. V. Hryshko, V. M. Stiffel, D. M. Christensen, and D. M. Bers. 1996. J. Mol. Cell Cardiol. 28: 79-93.
[247] Needleman and Wunsch. 1970J; Mol. Biol. 48: 443-453.
[248] Niggli, E. 1999. Annu Rev Physiol 61: 311-335.
[249] O'Reilly, F. M. and M. Ronjat. 1999. Biophys. J. 76: A466- (abstract).
[250] Osterland, J. C., S. M. Hayek, X. Xu, M. B. Bhat, and J. Ma. 1999. Biophys. J 76: A467 (green).
[251] Stern, M. D. and E. G. Lakatta. 1992. FASEB J. 6: 3092-3100.
[252] Tanabe, T., H. Takeshima, A. Mikami, V. Flockerzi, H. Takahashi, K.Kangawa, M. Kojima, H. Matsuo, T. Hirose, and S. Numa. 1987. Nature 328: 313-318.
[253] Tanabe, T., K. G. Beam, B. A. Adams, T. Niidome, and S. Numa. 1990. Nature346: 567-568.
[254] Thompson, et al. 1994. Nucl. Acids Res. 22: 4673-4680
[255] Zaloga, G. P., P. R. Roberts, K. W. Black, M. Lin, G. Zapata-Sudo, R. T. Sudo, and T.E. Nelson. 1997. Am.J. Physiol. 272: H462-H468.
[256] Zhou, J., L. Cribbs, J. Yi, R. Shirokov, E. Perez-Reyes, and E. Rios. 1998. J. Biol. Chem. 273: 25503-25509.

权利要求:
Claims (55)
[1" claim-type="Currently amended] Contacting the cardiac lyanodine receptor calcium channel with a sufficient amount of dihydropyridine receptor polypeptide or derivative, homologue or analogue fragment to modulate the activity of the lyanodine channel. How to regulate activity.
[2" claim-type="Currently amended] The method of claim 1, wherein the method further comprises measuring the activity of the cardiac lianodine calcium channel.
[3" claim-type="Currently amended] The method of claim 1 or 2, wherein said regulation is upregulation.
[4" claim-type="Currently amended] The method of claim 3, wherein the fragments are applied at a concentration of about 1 nm to about 10 μM.
[5" claim-type="Currently amended] The method of claim 1 or 2, wherein said regulation is down-regulation.
[6" claim-type="Currently amended] The method of claim 5, wherein the fragments are applied at a concentration of at least about 10 μM.
[7" claim-type="Currently amended] The method of claim 1, wherein the fragment comprises at least five contiguous amino acid residues of the following peptide sequence.
Thr Ser Ala Gln Lys Xaa Xaa Xaa Xaa Glu Glu Xaa Xaa Arg Ser Lys
Xaa Xaa Xaa Xaa Xaa (SEQ ID NO: 1)
[8" claim-type="Currently amended] 8. The method of claim 7, wherein the peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser
Lys Gly Leu (SEQ ID NO: 3)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ser Arg Gly Leu (SEQ ID NO: 4)
(iii) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu Lys Glu Arg Lys Lys Leu
Ala Arg Thr Ala (SEQ ID NO: 5)
(iv) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu Lys Glu Arg Lys Lys Leu
Ala Arg Thr Ala (SEQ ID NO: 6)
(v) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Lys Lys Leu Ala
Arg Ala Asn (SEQ ID NO: 7)
[9" claim-type="Currently amended] 8. The method of claim 7, wherein said peptide comprises the motif RKRRK.
[10" claim-type="Currently amended] 10. The method of claim 9, wherein the peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu. Arg Lys Arg Arg Lys Met Ser Lys Gly Leu (SEQ ID NO: 2)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ala Arg Gly Leu (SEQ ID NO: 8)
(iii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser Xaa Gly Leu (SEQ ID NO: 9)
(iv) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ala Xaa Gly Leu (SEQ ID NO: 10) or a derivative, homologue or analog thereof.
[11" claim-type="Currently amended] The method of claim 1, wherein the peptide comprises at least 10 contiguous amino acid residues and more preferably at least 15-20 contiguous amino acid residues.
[12" claim-type="Currently amended] 12. The method of claim 11, wherein said fragment is a basic charged fragment.
[13" claim-type="Currently amended] (i) incubating the amount of dihydropyridine receptor polypeptide or homologue, analog or derivative fragment thereof that modulates cardiac RyR2 channel activity in the presence of a functional cardiac lianodine calcium channel under suitable conditions in which calcium channel activity can be modulated, Measuring the activity of the channel;
(ii) incubating the candidate peptide or non-peptide compound in the presence of the functional cardiac RyR2 calcium channel under suitable conditions in which calcium channel activity can be regulated by the dihydropyridine receptor polypeptide fragment or homologue, analog or derivative thereof; Measuring the activity of the channel; And
(iii) comparing the activity in (i) and (ii) to identify peptide or non-peptide modulators of cardiac lyanodine calcium channel.
[14" claim-type="Currently amended] The method of claim 13, wherein said regulation is up-regulation.
[15" claim-type="Currently amended] The method of claim 14, wherein the fragments are applied at a concentration of about 1 nm to about 10 μM.
[16" claim-type="Currently amended] The method of claim 15, wherein said regulation is down-regulation.
[17" claim-type="Currently amended] The method of claim 16, wherein the fragments are applied at a concentration of at least about 10 μM.
[18" claim-type="Currently amended] 18. The method of any of claims 13 to 17, wherein the fragment comprises the following peptide sequence.
Thr Ser Ala Gln Lys Xaa Xaa Xaa Xaa Glu Glu Xaa Xaa Arg Ser Lys
Xaa Xaa Xaa Xaa Xaa (SEQ ID NO: 1)
[19" claim-type="Currently amended] 19. The method of claim 18, wherein the peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser
Lys Gly Leu (SEQ ID NO: 3)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ser Arg Gly Leu (SEQ ID NO: 4)
(iii) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu Lys Glu Arg Lys Lys Leu
Ala Arg Thr Ala (SEQ ID NO: 5)
(iv) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu Lys Glu Arg Lys Lys Leu
Ala Arg Thr Ala (SEQ ID NO: 6)
(v) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Lys Lys Leu Ala
Arg Ala Asn (SEQ ID NO: 7)
[20" claim-type="Currently amended] 19. The method of claim 18, wherein said peptide sequence comprises the motif RKRRK.
[21" claim-type="Currently amended] The method of claim 20, wherein the peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu. Arg Lys Arg Arg Lys Met Ser
Lys Gly Leu (SEQ ID NO: 2)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ala Arg Gly Leu (SEQ ID NO: 8)
(iii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ser Xaa Gly Leu (SEQ ID NO: 9)
(iv) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ala Xaa Gly Leu (SEQ ID NO: 10) or derivatives, homologues or analogs thereof.
[22" claim-type="Currently amended] 22. The method of claim 13, wherein the peptide comprises at least 10 contiguous amino acid residues and more preferably at least 15-20 contiguous amino acid residues.
[23" claim-type="Currently amended] The method of claim 22, wherein the fragment is a basic charged fragment.
[24" claim-type="Currently amended] (i) identifying candidate agonists and antagonists of cardiac lianodine calcium channels;
(ii) determining whether the compounds of step (i) actually activate or inhibit the activity of the cardiac lianodine channel;
(iii) determining whether the compounds of step (ii) have a higher binding affinity for the cardiac lianodine calcium channel than any of SEQ ID NOs: 1 to 10; And
(iv) optionally, measuring a site of interaction between the compounds of step (iii) and the cardiac lyanodine calcium channel.
[25" claim-type="Currently amended] A method of determining whether a cardiac lianodine channel is open or has a high channel open probability, the method comprising contacting a cardiac lianodine channel with an amount of a dihydropyridine receptor polypeptide fragment at a time and under conditions sufficient to result in binding to lianodine. Wherein the binding of the peptide to lianodine exhibits a high channel open probability, and the non-specific peptide bond of the peptide and channel pores exhibits a low channel open probability.
[26" claim-type="Currently amended] The method of claim 25, wherein the fragment comprises at least five consecutive amino acid residues of the peptide sequence.
Thr Ser Ala Gln Lys Xaa Xaa Xaa Xaa Glu Glu Xaa Xaa Arg Ser Lys
Xaa Xaa Xaa Xaa Xaa (SEQ ID NO: 1)
[27" claim-type="Currently amended] 27. The method of claim 26, wherein the peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser
Lys Gly Leu (SEQ ID NO: 3)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser Arg Gly Leu (SEQ ID NO: 4)
(iii) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu Lys Glu Arg Lys Lys Leu Ala Arg Thr Ala (SEQ ID NO: 5)
(iv) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu LysG Arg Lys Lys Leu Ala
Arg Thr Ala (SEQID NO: 6)
(v) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Lys Lys Leu Ala
Arg Ala Asn (SEQ ID NO: 7)
[28" claim-type="Currently amended] 27. The method of claim 26, wherein said peptide sequence comprises the motif RKRRK.
[29" claim-type="Currently amended] 29. The method of claim 28, wherein said peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser
Lys Gly Leu (SEQ ID NO: 2)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ala Arg Gly Leu (SEQ ID NO: 8)
(iii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ser Xaa Gly Leu (SEQ ID NO: 9)
(iv) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ala Xaa Gly Leu (SEQ ID NO: 10) or derivatives, homologues or analogs thereof.
[30" claim-type="Currently amended] The method of claim 25, wherein the peptide comprises at least 10 contiguous amino acid residues and more preferably at least 15-20 contiguous amino acid residues.
[31" claim-type="Currently amended] 31. The method of claim 30, wherein said fragment is a basic charged fragment.
[32" claim-type="Currently amended] Administering an effective amount of the dihydropyridine receptor (DHPR) polypeptide fragment at a time and condition sufficient to treat enhanced cardiac contractility or cardiac dysfunction, thereby treating a cardiac dysfunction in a human or animal subject. How to treat cardiac dysfunction.
[33" claim-type="Currently amended] 31. The cardiac dysfunction of claim 30, wherein the cardiac dysfunction is cardiomyopathy, ischemic heart disease, systemic inflammatory conditions such as sepsis, cardiac hypertrophy (calcium overload), cardiomyopathy such as arrhythmia, left ventricular dysplasia type 2 (ARVD2), and drugs ( For example, cocaine) -induced cardiomyopathy, infarction, rhythm disorders, congestive heart failure, or heart attack.
[34" claim-type="Currently amended] 34. The method of claim 32 or 33, wherein said fragment comprises at least five consecutive amino acid residues of the peptide sequence.
Thr Ser Ala Gln Lys Xaa Xaa Xaa Xaa Glu Glu Xaa Xaa Arg Ser Lys
Xaa Xaa Xaa Xaa Xaa (SEQ ID NO: 1)
[35" claim-type="Currently amended] 35. The method of claim 34, wherein the peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser
Lys Gly Leu (SEQ ID NO: 3)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ser Arg Gly Leu (SEQ ID NO: 4)
(iii) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu Lys Glu Arg Lys Lys Leu
Ala Arg Thr Ala (SEQ ID NO: 5)
(iv) Thr Ser Ala Gln Lys Glu Glu Glu Glu Glu Lys Glu Arg Lys Lys Leu
Ala Arg Thr Ala (SEQ ID NO: 6)
(v) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Lys Lys Leu Ala
Arg Ala Asn (SEQ ID NO: 7)
[36" claim-type="Currently amended] 34. The method of claim 32 or 33, wherein said peptide sequence comprises the motif RKRRK.
[37" claim-type="Currently amended] 37. The method of claim 36, wherein said peptide sequence corresponds to any one of the following peptide sequences.
(i) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser
Lys Gly Leu (SEQ ID NO: 2)
(ii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ala Arg Gly Leu (SEQ ID NO: 8)
(iii) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met
Ser Xaa Gly Leu (SEQ ID NO: 9)
(iv) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ala
Xaa Gly Leu (SEQ ID NO: 10) or derivatives, homologues or analogs thereof.
[38" claim-type="Currently amended] 38. The method of any one of claims 32 to 37, wherein the peptide comprises at least 10 contiguous amino acid residues and more preferably at least 15-20 contiguous amino acid residues.
[39" claim-type="Currently amended] 39. The method of claim 38, wherein said fragment is a basic charged fragment.
[40" claim-type="Currently amended] At least five consecutive amino acid residues or homologs, analogs or derivatives thereof of the peptides set forth in any one of SEQ ID NOs: 1 to 10 for modifying defective calcium signaling by modifying the activity of the cardiac lianodine calcium channel. Using a fragment of the dihydropyridine receptor polypeptide.
[41" claim-type="Currently amended] 41. Use according to claim 40, wherein said peptide comprises at least 10 contiguous amino acid residues and more preferably at least 15-20 contiguous amino acid residues.
[42" claim-type="Currently amended] 42. Use according to claim 40 or 41, wherein said impaired calcium signaling induces chronic hypertrophy, dilated cardiomyopathy or heart failure.
[43" claim-type="Currently amended] 42. The method of claim 40 or 41, wherein the peptide or homologue, analog or derivative thereof can enhance contractile force and further increase intracellular calcium concentration (ie, [Ca ²⁺ ] _i ) during the systolic phase. And furthermore, during the diastolic phase, administration at a dose that can further reduce [Ca ²⁺ ] _i .
[44" claim-type="Currently amended] The method of claim 43 wherein the peptide or a homologue, analogue or derivative is characterized by causing the systolic [Ca ^2+] increases at least about 3% to about 5% compared to the systolic _i [Ca ^2+] _i use.
[45" claim-type="Currently amended] 44. The method of claim 43, characterized in that used to induce the peptide or a homologue, analogue or derivative diastolic [Ca ^2+] i diastolic [Ca ^2+] i of at least approximately 3% to 5% reduction in comparison with .
[46" claim-type="Currently amended] 46. The method of claim 44 or 45, up to at least about 10% or 15%, even more preferably at least about 20%, 25%, 30, as compared to systolic [Ca ²⁺ ] i or diastolic [Ca ²⁺ ] i. Use characterized in that systolic [Ca ²⁺ ] i is increased or diastolic [Ca ²⁺ ] i is reduced by%, 40% or 50%.
[47" claim-type="Currently amended] 47. The use according to any one of claims 40 to 46, wherein said administered peptide causes an improvement in cardiac contractile efficacy.
[48" claim-type="Currently amended] 48. The use according to claim 47, wherein the cardiac contraction is enhanced by causing an increase of at least about 5% or 10% of the full-supplementary ejection workload within 0.5-1.0 hours after administration.
[49" claim-type="Currently amended] 49. The use of claim 48, wherein the heart contraction is enhanced by about 15%, 20%, 30%, 40%, 50%, 55%, 60% or 70%.
[50" claim-type="Currently amended] In the manufacture of a medicament for the treatment of cardiac dysfunction in a human or animal subject comprising at least five consecutive amino acid residues of the peptides or homologues, analogs or derivatives thereof set forth in any one of SEQ ID NOs: 1-10. Use of dihydropyridine receptor polypeptide fragments.
[51" claim-type="Currently amended] 51. The method of claim 50, wherein the cardiac dysfunction is cardiomyopathy, ischemic heart disease, systemic inflammatory conditions such as sepsis, cardiac hypertrophy (calcium overload), cardiomyopathy such as arrhythmia-like ventricular dysfunction type 2 (ARVD2), and drugs ( For example, cocaine) -induced cardiomyopathy, infarction, rhythm disorders, congestive heart failure, or heart attack.
[52" claim-type="Currently amended] 52. Use according to claim 50 or 51, wherein the peptide comprises at least 10 contiguous amino acid residues and more preferably at least 15-20 contiguous amino acid residues.
[53" claim-type="Currently amended] One or more pharmaceutically acceptable carriers with a dihydropyridine receptor polypeptide fragment comprising at least about 5 consecutive amino acid residues of the peptides set forth in any one of SEQ ID NOs: 1-10, or homologues, analogs or derivatives thereof And / or a diluent.
[54" claim-type="Currently amended] 54. The pharmaceutical composition of claim 53, wherein the peptide comprises at least 10 contiguous amino acid residues and more preferably at least 15-20 contiguous amino acid residues.
[55" claim-type="Currently amended] The pharmaceutical composition of claim 53 or 54 for use in a method according to any one of claims 32 to 39.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Prekeris et al.2000|A Rab11/Rip11 protein complex regulates apical membrane trafficking via recycling endosomes

---

Nishimune et al.1998|NSF binding to GluR2 regulates synaptic transmission

---

Pepinsky et al.1998|Identification of a palmitic acid-modified form of human Sonic hedgehog

---

Michel et al.2002|AKAP mediated signal transduction

---

Srivastava et al.1998|Novel anchorage of GluR2/3 to the postsynaptic density by the AMPA receptor–binding protein ABP

---

Mirza et al.1996|The proteinase activated receptor-2 | mediates mitogenic responses in human vascular endothelial cells.

---

US9746463B2|2017-08-29|Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass

---

US7834143B2|2010-11-16|Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor

---

US7319092B2|2008-01-15|Methods of suppressing microglial activation

---

Chen2000|Growth hormone secretagogue actions on the pituitary gland: multiple receptors for multiple ligands?

---

Brender et al.2008|A single mutation in the nonamyloidogenic region of islet amyloid polypeptide greatly reduces toxicity

---

Malbon et al.2004|AKAPs | and molecules that compose their G-protein-coupled receptor signalling complexes

---

Mahata et al.1997|Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.

---

AU782678B2|2005-08-18|Interaction of NMDA receptor with protein tyrosine phosphatase

---

Yang et al.2005|β-cell CaV channel regulation in physiology and pathophysiology

---

EP1420800B1|2011-09-28|Modulation of insulin-regulated aminopeptidase |/angiotensin iv | receptor activity

---

JP4295449B2|2009-07-15|IgE-dependent histamine-releasing factor | receptor, HRF-binding peptides and nucleic acids encoding them, and uses thereof

---

Wisniewski et al.1994|Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

---

Tang et al.1996|Initial externalization followed by internalization of beta-adrenergic receptors in rat heart during sepsis

---

Mann et al.2004|Novel lipid modifications of secreted protein signals

---

Saenz de Tejada et al.1991|Endothelin: localization, synthesis, activity, and receptor types in human penile corpus cavernosum

---

Oda et al.2005|Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure

---

US7790683B2|2010-09-07|Leptin-related peptides

---

AU772278B2|2004-04-22|Leptin-related peptides

---

Firestein et al.1999|Cypin: a cytosolic regulator of PSD-95 postsynaptic targeting

同族专利:

---

公开号 | 公开日

---

US20050049198A1|2005-03-03|

---

CA2446839A1|2002-11-21|

---

ZA200309727B|2005-08-01|

---

BR0210902A|2004-06-08|

---

NZ529940A|2006-08-31|

---

JP2004535397A|2004-11-25|

---

CN1516596A|2004-07-28|

---

WO2002092119A1|2002-11-21|

---

EP1392344A4|2005-09-21|

---

EP1392344A1|2004-03-03|

---

AUPR506601A0|2001-06-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-05-17|Priority to AUPR5066

---

2001-05-17|Priority to AUPR5066A

---

2002-05-17|Application filed by 디 오스트레일리언 내셔널 유니버시티

---

2002-05-17|Priority to PCT/AU2002/000608

---

2004-01-07|Publication of KR20040002970A

优先权:

---

申请号 | 申请日 | 专利标题

---

AUPR5066|2001-05-17|

---

AUPR5066A|AUPR506601A0|2001-05-17|2001-05-17|Method of modulating the activity of calcium channels in cardiac cells and reagents therefor|

---

PCT/AU2002/000608|WO2002092119A1|2001-05-17|2002-05-17|Method of modulating the activity of calcium channels in cardiac cells and reagents therefor|